Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05349682

Bayer OA Knee Pain Pilot

The objective of this study is to investigate if MRI can be used to evaluated effect of knee artery embolization for knee osteoarthritis. Participants be evaluated in clinic, obtain a knee MRI, undergo embolization of the symptomatic knee, and follow up in clinic at 1, 6, and 12 months after embolization. A second MRI is obtained 6 months after embolization. Participants will keep a record of their pain level and treatment and answer questionnaires at each visit.

In addition, this study aims to determine the effects of knee artery embolization on the amount of opioid (pain reliever drugs) needed to manage osteoarthritis-associated pain and change in quality of life.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Osteoarthritis, Knee Arthritis Joint Diseases Musculoskeletal Diseases Osteoarthritis Rheumatic Diseases

Age range

25 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Medical University of South Carolina

Charleston, South Carolina, 29425, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 25 to 90
  • Symptomatic osteoarthritis of one or both knees, with Kellgren-Lawrence grade 1-3 assessed by weight-bearing knee radiography, including post-traumatic osteoarthritis
  • One or more months of non-surgical therapy for knee pain such as joint injections, oral NSAIDs, or opioid analgesia
  • Subjects able to provide informed consent. As this is a study of pain, patients must be able to consent for themselves.
  • Patients without contraindication to MRI imaging with gadolinium-based contrast.

Exclusion criteria

  • Anaphylaxis to gadolinium or iodinated contrast media
  • Impaired renal function with GFR <30ml/min
  • Severe atherosclerotic disease of the lower extremity precluding percutaneous angiographic access to the involved geniculate artery(ies)
  • Active septic arthritis of the symptomatic knee within 2 months of screening
  • Malignancy of the involved knee
  • Rheumatoid Arthritis or Gout
  • Prior knee surgery
  • Hemarthrosis
  • Females who are pregnant or plan to become pregnant during the study. All participants able to become pregnant will be administered a urine pregnancy test.

Treatment and study plan

dynamic contrast enhanced MRI

Diagnostic Test

An MRI study of the knee will be done to check the degree of osteoarthritis and blood flow to the affected knee. This scan will take about 1-2 hour(s).

Geniculate artery embolization

Procedure

The physician will perform a diagnostic angiography, where they will take pictures of vessels near the knee that will be treated. Once the artery to be treated is identified, the doctor will guide a thin wire called a microwire, and a plastic tube called a microcatheter to the targeted artery, and more pictures of vessels at the knee will be taken. This picture will be used to see if there are any abnormal vessels at the knee, such as abnormal blood flow, abnormal vessel connections (between the veins and arteries), or new blood vessel growth. Once the targeted artery at the knee is confirmed, the doctor will inject enough particle embolic (Embozene) to slow or stop the blood flow in the geniculate artery. Once all vessels are treated, a final angiogram (pictures of blood vessels) will be performed to ensure that the blood flow has slowed.

Primary outcomes

  1. Change in enhancement time intensity curves obtained from CE-MRI

    Time frame: change from baseline at 6 month post procedure

    To evaluate the effects of particle embolization on knee osteoarthritis progression using enhancement time intensity curves obtained from CE-MRI (Contrast Enhanced Magnetic Resonance Imaging)

  2. Change in Whole-Organ Magnetic Resonance Scoring (WORMS)

    Time frame: change from baseline at 6 month post procedure

    To evaluate the effects of particle embolization on knee osteoarthritis progression using the WORMS scoring system. The higher the score, the worse the OA is. The scoring ranges from 0-332.

  3. Change in Multicenter Osteoarthritis Study (MOST) grading system for synovitis

    Time frame: change from baseline at 6 month post procedure

    To evaluate the effects of particle embolization on knee osteoarthritis progression using the MOST grading system for synovitis. The higher the score, the worse the synovial inflammation is. The scoring ranges from 0-13. 0-4 normal or equivocal synovitis, 5-8 mild synovitis, 9-12 moderate synovitis, and 13 or greater is severe synovitis.

  4. Number of participants with 50% reduction in pain scores

    Time frame: change from baseline at 1 month post procedure

    To determine the effects of geniculate artery embolization (GAE) on opioid requirements for managing OA associated pain. Assess pain using Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Knee Injury and Osteoarthritis Outcome Score (KOOS). WOMAC is scored from 0-20 for pain, 0-8 for stiffness, and 0-68 for physical function. Higher scores indicate worse pain, stiffness, and function limitation. KOOS score is from 0-100, 0 being extreme problems and 100 being no problems.

  5. Number of participants with 50% reduction in pain scores

    Time frame: change from baseline at 6 month post procedure

    To determine the effects of geniculate artery embolization (GAE) on opioid requirements for managing OA associated pain. Assess pain using Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Knee Injury and Osteoarthritis Outcome Score (KOOS). WOMAC is scored from 0-20 for pain, 0-8 for stiffness, and 0-68 for physical function. Higher scores indicate worse pain, stiffness, and function limitation. KOOS score is from 0-100, 0 being extreme problems and 100 being no problems.

  6. Number of participants with 50% reduction in pain scores

    Time frame: change from baseline at 12 month post procedure

    To determine the effects of geniculate artery embolization (GAE) on opioid requirements for managing OA associated pain. Assess pain using Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and Knee Injury and Osteoarthritis Outcome Score (KOOS). WOMAC is scored from 0-20 for pain, 0-8 for stiffness, and 0-68 for physical function. Higher scores indicate worse pain, stiffness, and function limitation. KOOS score is from 0-100, 0 being extreme problems and 100 being no problems.

  7. Incidence of adverse events associated with GAE

    Time frame: 1 month post procedure

    The number of adverse events per participant

  8. Incidence of adverse events associated with GAE

    Time frame: 6 month post procedure

    The number of adverse events per participant

  9. Incidence of adverse events associated with GAE

    Time frame: 12 month post procedure

    The number of adverse events per participant

Sponsors and collaborators

Lead sponsor

Medical University of South Carolina

Other

Collaborators

  • Bayer

Registry information

Official study title

Transcatheter Geniculate Arterial Embolization: Treatment and Monitoring of Response

Important dates

Study start
2022
Primary completion
2026
Study completion
2026
First posted
Apr 27, 2022
Registry last updated
Jul 22, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.